Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E61.04 EPS (ttm)2.93 Insider Own0.70% Shs Outstand226.15M Perf Week2.91%
Market Cap40.45B Forward P/E29.95 EPS next Y5.97 Insider Trans-7.29% Shs Float225.33M Perf Month-10.25%
Income592.60M PEG3.62 EPS next Q1.01 Inst Own98.30% Short Float2.05% Perf Quarter8.54%
Sales2.39B P/S16.92 EPS this Y156.70% Inst Trans14.13% Short Ratio2.53 Perf Half Y-3.12%
Book/sh42.29 P/B4.23 EPS next Y23.29% ROA9.20% Target Price225.61 Perf Year6.27%
Cash/sh6.61 P/C27.07 EPS next 5Y16.84% ROE12.80% 52W Range150.06 - 208.88 Perf YTD-3.33%
Dividend- P/FCF65.19 EPS past 5Y14.90% ROI19.50% 52W High-14.37% Beta0.69
Dividend %- Quick Ratio3.00 Sales past 5Y42.00% Gross Margin90.70% 52W Low19.19% ATR6.67
Employees2273 Current Ratio3.30 Sales Q/Q24.10% Oper. Margin35.00% RSI (14)44.79 Volatility5.28% 3.49%
OptionableYes Debt/Eq0.41 EPS Q/Q0.00% Profit Margin24.80% Rel Volume0.81 Prev Close179.82
ShortableYes LT Debt/Eq0.39 EarningsJul 30 BMO Payout0.00% Avg Volume1.82M Price178.86
Recom1.80 SMA20-3.64% SMA50-6.08% SMA200-1.86% Volume1,477,771 Change-0.53%
Jul-31-15Reiterated UBS Buy $220 → $223
Jul-31-15Reiterated Stifel Buy $239 → $257
Jul-31-15Reiterated Brean Capital Buy $213 → $221
Jul-27-15Resumed JP Morgan Overweight
May-07-15Upgrade Nomura Neutral → Buy
May-07-15Reiterated Brean Capital Buy $215 → $213
Jan-30-15Reiterated Stifel Buy $230 → $236
Jan-08-15Reiterated UBS Buy $220 → $213
Apr-25-14Reiterated Stifel Buy $219 → $220
Mar-11-14Reiterated UBS Buy $185 → $202
Mar-11-14Reiterated Stifel Buy $207 → $219
Mar-06-14Reiterated Barclays Overweight $181 → $193
Feb-10-14Reiterated Deutsche Bank Buy $125 → $205
Jan-31-14Reiterated Stifel Buy $138 → $207
Jan-31-14Reiterated Canaccord Genuity Buy $161 → $200
Jan-31-14Reiterated Barclays Overweight $141 → $181
Jan-30-14Reiterated Brean Capital Buy $142 → $200
Jan-10-14Reiterated Barclays Overweight $127 → $141
Jan-06-14Reiterated UBS Buy $130 → $150
Jan-06-14Reiterated Canaccord Genuity Buy $138 → $161
Aug-28-15 03:34PM  Gilead & Amgen Account for Nearly 75% of the Biotech Profit Pool at Barrons.com
09:36AM  UBS Picks 22 Stocks for Their 'Cash Cushions' for Times of Market Volatility at TheStreet
Aug-21-15 05:39PM  How Big Biotech Spends Its Money at Barrons.com
08:39AM  Falling Earnings Estimates Signal Weakness Ahead for Alexion Pharmaceuticals (ALXN)
Aug-19-15 06:29PM  Celgene May be The Single Best Biotech in the World
08:16AM  This Drugmaker's Incredible Run Looks Far From Done at Motley Fool
Aug-18-15 09:52AM  Omeros Reports Positive Study Data, Shares Surge at The Wall Street Journal
Aug-17-15 04:06PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events
09:31AM  Dont Miss White-Hot Baker Bros. New Healthcare Picks at Insider Monkey
Aug-15-15 03:07PM  The 5 Most Expensive Drugs in the World in 2015 at Motley Fool
Aug-14-15 02:04PM  Biotech, Semiconductor ETFs Enter Dangerous Ground at Investor's Business Daily
01:02PM  Short Sellers Wary Of Biotech Stocks
Aug-13-15 04:17PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K/A, Financial Statements and Exhibits
09:20AM  JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015 at 24/7 Wall St.
Aug-10-15 08:20AM  3 Large Biotech Stocks to Buy Despite Higher Interest Rates Coming at 24/7 Wall St.
Aug-07-15 02:39PM  The Historical Correlation Between Biotech Stocks And Interest Rates
01:00PM  Whats Shires plan for Baxalta? Inside CEO Flemming Ornskovs head at bizjournals.com
10:55AM  Will Gilead Make 'Transformative Transaction'?
Aug-06-15 05:14PM  Corruption Currents: Hacking Computers to Send Data Via Sound Waves at The Wall Street Journal
01:04PM  ALEXION PHARMACEUTICALS INC Financials
08:33AM  Amgen, Inc. Earnings Analysis: By the Numbers Q2*, 2015
Aug-04-15 08:35AM  3 Potential Huge Takeover Targets in Biotech at 24/7 Wall St.
Aug-03-15 08:09PM  10-Q for Alexion Pharmaceuticals, Inc. at Company Spotlight
Jul-31-15 01:54PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
09:41AM  Alexion Pharmaceuticals (ALXN) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
Jul-30-15 09:31PM  Edited Transcript of ALXN earnings conference call or presentation 30-Jul-15 2:00pm GMT
06:49PM  Amgen, Alexion Top Views, But Their Outlooks Differ
05:10PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:29PM  Alexion Facing Big Costs, Guidance Disappoints at Investor's Business Daily
04:17PM  Alexion Pharmaceuticals (ALXN) Stock Gained on Earnings as Guidance Lowered at TheStreet
02:50PM  Alexion Misses on Earnings in Q2, 2015 Outlook Revised - Analyst Blog
10:00AM  Alexion Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today
08:53AM  Celgene Corp. Earnings Analysis: By the Numbers
07:54AM  Alexion (ALXN) Misses on Q2 Earnings, Revises Outlook - Tale of the Tape
06:42AM  Alexion tops Street 2Q forecasts
06:30AM  Alexion Reports Second Quarter 2015 Results Business Wire
Jul-28-15 06:46PM  Big Annual Earnings Estimates Matter To Find Winning Stocks
03:45PM  Will Rising Costs Hurt Alexion (ALXN) Earnings in Q2? - Analyst Blog
Jul-27-15 03:24PM  Is Gilead Sciences About to Make an Acquisition?
08:18AM  JP Morgan Moves Alexion Pharma To Overweight, Says Strensiq And Kanuma Are $1.7B Opportunity
Jul-20-15 04:58PM  What to Expect from Biogen and Celgene at Barrons.com
08:50AM  4 Large Cap Biotech Stocks to Buy Before Earnings at 24/7 Wall St.
Jul-14-15 06:51PM  Alexion, Incyte Stage Breakouts at Investor's Business Daily
Jul-13-15 06:43PM  Big Cap 20: Biotech Red-Hot As Medicals Stay Dominant at Investor's Business Daily
10:00AM  Alexion Pharmaceuticals to Report Second Quarter 2015 Results on Thursday, July 30, 2015 Business Wire
09:54AM  Short Sellers Shy Away From Biotech Stocks
Jul-12-15 12:09PM  5 Trade Ideas for Monday: American Eagle, Alexion, Atmel, Federated & Lending Tree
Jul-10-15 03:04PM  How Rare-Disease Drugmaker Alexion Pharmaceuticals Found Its Groove in June at Motley Fool
12:59PM  Halftime's hottest trades: LNKD, CUDA, ALXN & QCOM
10:06AM  Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns at Insider Monkey
Jul-09-15 09:30AM  The Zacks Analyst Blog Highlights: Vertex, Biogen, Applied Genetic, Gilead and Alexion - Press Releases
Jul-07-15 04:45PM  Alexion Hypophosphatasia Drug Strensiq Approved in Japan - Analyst Blog
05:49AM  Singapore's giant wealth fund still bullish on China at CNBC
Jul-06-15 06:53PM  Big Cap 20: Does Edwards Lifesciences Have More Left? at Investor's Business Daily
06:00AM  Strensiq® (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP) Business Wire
Jul-05-15 08:02AM  The Competitive Advantage of the Best Biotech Stocks at Motley Fool
Jul-01-15 10:24AM  10 Worst Health Care Stocks in the S&P 500 at TheStreet
Jun-30-15 10:58AM  Why Alexion Stock Could Rip
Jun-29-15 04:25PM  Alexion's Strensiq and Kanuma Get Positive CHMP Opinions - Analyst Blog
Jun-26-15 07:13AM  Europe gives green light to new Novartis, Alexion drugs Reuters
07:11AM  Alexion Receives CHMP Positive Opinions for Strensiq (asfotase alfa) and Kanuma (sebelipase alfa) in the European Union Business Wire
Jun-23-15 01:30PM  This Firm Controls An Incredibly Profitable Niche
08:16AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
06:30AM  Alexion Completes Acquisition of Synageva Business Wire
Jun-22-15 06:30AM  Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer Business Wire
Jun-20-15 09:35AM  5 Unusual Movers in the S&P 500 at 24/7 Wall St.
Jun-19-15 07:50AM  Summer is for healthcare
Jun-16-15 08:02AM  Top Health Care Funds: Can Outperformance Continue? at Investor's Business Daily
Jun-12-15 12:38PM  Alnylam Reports Data on Potential Alexion Rival Drug at Investor's Business Daily
Jun-11-15 07:01AM  Gaps in drugs pipelines spark a flurry of takeover activity at Financial Times
03:38AM  Edited Transcript of ALXN presentation 10-Jun-15 3:40pm GMT
Jun-10-15 07:47AM  Short-term bulls targeting Alexion +6.82%
Jun-04-15 02:57PM  Alexion: Don't Fear the Competition at Barrons.com
Jun-02-15 10:00AM  Alexion to Present at Investor Conferences Business Wire
May-29-15 04:20PM  Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexions Pending Acquisition of Synageva Business Wire
May-27-15 03:05PM  The Synageva BioPharmaAlexion Deal Spread Has Some Hair on It
May-22-15 03:24PM  Summer stock picks
02:45PM  A Beautiful Biotech Summer? at Barrons.com
May-21-15 03:57PM  Pall-Danaher Transaction: What You Should Know about Danaher
03:57PM  Pall-Danaher Transaction: An Overview of Pall
May-20-15 01:52PM  Achillion Dives As J&J Hep C Deal Chills Buyout Buzz at Investor's Business Daily
09:46AM  Gilead Sciences: Little Risk From Achillion's Hep-C Partnership With J&J at Barrons.com
08:25AM  Do R&D Costs Matter When It Comes To Drug Pricing? at Forbes
May-14-15 11:06AM  Should You Set Up the Synageva BioPharmaAlexion Spread?
07:54AM  Platinum picks for your portfolio
May-13-15 03:07PM  Alexion Pharmaceuticals: A Focus on Treating Rare Disorders
May-12-15 05:21PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
04:25PM  The SynagevaAlexion Merger: Stock and Cash Considerations
04:25PM  Alexion Pharmaceuticals Pays up to Get Synageva BioPharma
07:00AM  Move Over, Elon Musk. CNBC's No. 1 Disruptor This Year is a Biotech Company, Moderna at Forbes
07:00AM  Disruptor 50: No.1 Moderna Therapeutics at CNBC
07:00AM  A hot biotech that may be the next Genentech at CNBC
May-08-15 06:22PM  SYNAGEVA BIOPHARMA CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
02:17PM  2 reasons we're not in biotech bubble: Pro
12:47PM  Week in Review, May 9 at Financial Times
11:03AM  Jobless Claims Are Driven by Technology: XLK Up and QQQ Gains
09:21AM  Alexion Pharmaceuticals, Inc. (ALXN) in Focus: Stock Jumps 5.1% - Tale of the Tape
May-07-15 04:25PM  Alexion to Buy Synageva for $8.4B: Alexion Down, Synageva Up - Analyst Blog +5.13%
04:03PM  Morgan Stanley: Market's Reaction To Linger For Alexion Pharmaceuticals
03:30PM  Here's What Canaccord Learned After Spending A Day With Synageva's Management
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hallal DavidCEOAug 07Sale190.0132962,513143,187Aug 11 05:53 PM
Carmichael ClareEVP, Chief HR OfficerAug 07Sale190.0116330,97227,461Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 07Sale190.0113525,65142,283Aug 11 05:53 PM
BELL LEONARDDirectorAug 07Sale190.011,003190,580919,088Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 05Option Exercise92.6520,0001,853,00042,428Aug 05 06:08 PM
Moriarty John BEVP & General CounselAug 05Sale198.4410,0101,986,37732,418Aug 05 06:08 PM
BELL LEONARDDirectorAug 04Sale196.522,200432,344920,091Aug 05 06:08 PM
Sinha VikasEVP & CFOAug 04Sale196.52675132,651166,646Aug 05 06:08 PM
Carmichael ClareEVP, Chief HR OfficerAug 04Sale196.5218536,35627,624Aug 05 06:09 PM
Hallal DavidCEOAug 04Sale196.52612120,270143,516Aug 05 06:09 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Option Exercise130.2943,5005,667,48876,393Aug 05 06:09 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Sale196.5243,5008,548,41832,893Aug 05 06:09 PM
BELL LEONARDDirectorJun 18Sale179.6327,8355,000,001922,291Jun 19 07:09 PM
Moriarty John BEVP & General CounselJun 11Sale170.00914155,38032,428Jun 12 06:26 PM
Monnet DominiqueSVP, Chief Marketing OfficerMay 20Sale162.4025641,5748,787May 22 05:30 PM
MACKAY MARTINEVP & Global Head of R&DMay 14Sale160.334,056650,29832,893May 22 05:30 PM
Islam SaqibEVP, Chief Strat & Port. Off.Apr 27Sale181.576,0321,095,23039,868Apr 30 09:45 PM
BELL LEONARDCEOMar 19Sale188.0715,9523,000,093949,426Mar 20 05:02 PM
MACKAY MARTINEVP & Global Head of R&DMar 02Sale180.3437066,72636,949Mar 03 09:13 PM
Sinha VikasEVP & CFOMar 02Sale180.3448787,826167,321Mar 03 09:13 PM
O'Neill JulieEVP. Global OperationsMar 02Sale180.346,5651,183,93222,090Mar 03 09:13 PM
Islam SaqibEVP, Chief Strat & Port. Off.Mar 02Sale180.3422841,11839,432Mar 03 09:12 PM
Moriarty John BEVP & General CounselMar 02Sale180.3428050,49533,342Mar 03 09:13 PM
BELL LEONARDCEOMar 02Sale180.341,230221,818965,378Mar 03 09:11 PM
Hallal DavidChief Operating OfficerMar 02Sale180.34730131,648132,858Mar 03 09:11 PM
Carmichael ClareEVP, Chief HR OfficerMar 02Sale180.34706127,32027,809Mar 03 09:12 PM
MACKAY MARTINEVP & Global Head of R&DFeb 10Sale173.973,897677,95632,219Feb 12 09:07 PM
Monnet DominiqueSVP, Chief Marketing OfficerFeb 10Sale171.1532555,6245,213Feb 12 09:07 PM
O'Neill JulieEVP. Global OperationsFeb 10Sale171.15795136,06423,555Feb 12 09:07 PM
Sinha VikasEVP & CFOFeb 10Sale171.151,985339,733162,708Feb 12 09:08 PM
BELL LEONARDCEOFeb 10Sale171.155,740982,401944,308Feb 12 09:06 PM
Hallal DavidChief Operating OfficerFeb 10Sale171.151,980338,877124,033Feb 12 09:06 PM
Carmichael ClareEVP, Chief HR OfficerFeb 10Sale171.151,490255,01421,670Feb 12 09:06 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 10Sale171.151,500256,72534,560Feb 12 09:06 PM
Moriarty John BEVP & General CounselFeb 10Sale171.151,490255,01426,777Feb 12 09:07 PM
Sinha VikasEVP & CFOFeb 09Sale174.182,703470,810164,693Feb 09 08:48 PM
Moriarty John BEVP & General CounselFeb 09Sale174.161,455253,40328,267Feb 09 08:48 PM
BELL LEONARDCEOFeb 09Sale173.988,6601,506,667950,048Feb 09 08:46 PM
Hallal DavidChief Operating OfficerFeb 09Sale173.932,920507,876126,013Feb 09 08:46 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale173.751,665289,29423,160Feb 09 08:47 PM
Hallal DavidChief Operating OfficerFeb 04Sale174.38608106,023117,243Feb 05 08:10 PM
BELL LEONARDCEOFeb 04Sale174.352,223387,583924,718Feb 05 08:10 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale174.3520736,09016,065Feb 05 08:09 PM
Sinha VikasEVP & CFOFeb 04Sale174.37676117,874155,706Feb 05 08:10 PM
Sinha VikasEVP & CFOFeb 03Sale174.06895155,784156,382Feb 05 08:10 PM
BELL LEONARDCEOFeb 03Sale174.253,000522,750926,941Feb 05 08:10 PM
Hallal DavidChief Operating OfficerFeb 03Sale174.02765133,125117,851Feb 05 08:10 PM
Hallal DavidChief Operating OfficerDec 18Sale182.035,4941,000,073113,122Dec 19 04:49 PM
BELL LEONARDCEODec 18Sale182.0313,7352,500,182929,941Dec 19 04:49 PM
BELL LEONARDCEODec 17Option Exercise22.9016,680381,972960,356Dec 19 04:49 PM
BELL LEONARDCEODec 17Sale177.8416,6802,966,315943,676Dec 19 04:49 PM
Brennan David RDirectorDec 15Buy186.9950093,4951,268Dec 16 05:18 PM
Moriarty John BEVP & General CounselDec 11Sale195.533,570698,04220,962Dec 15 06:50 PM
Veneman Ann MDirectorDec 11Sale193.031,235238,3923,447Dec 15 06:50 PM
BELL LEONARDCEODec 09Option Exercise22.9016,665381,629960,341Dec 09 07:37 PM
BELL LEONARDCEODec 09Sale199.9416,6653,332,000943,676Dec 09 07:37 PM
BELL LEONARDCEODec 08Option Exercise21.8159,9341,307,1561,003,610Dec 09 07:37 PM
BELL LEONARDCEODec 08Sale198.8859,93411,919,423943,676Dec 09 07:37 PM
BELL LEONARDCEODec 05Option Exercise17.9856,7211,019,8441,000,397Dec 09 07:37 PM
BELL LEONARDCEODec 05Sale197.1256,72111,181,101943,676Dec 09 07:37 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Option Exercise57.0210,000570,20026,272Dec 08 04:59 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Sale196.2510,0001,962,50016,272Dec 08 04:59 PM
KELLER WILLIAM RDirectorDec 04Sale196.255,000981,2507,276Dec 08 04:59 PM
Sinha VikasEVP & CFODec 03Option Exercise19.1550,000957,400212,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 03Sale198.3650,0009,918,230162,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Option Exercise17.9825,000449,500187,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Sale200.1625,0005,004,000162,770Dec 04 05:20 PM
BELL LEONARDCEONov 20Sale191.965,2101,000,112943,676Nov 24 05:28 PM
Sinha VikasEVP & CFONov 06Option Exercise17.985,693102,360168,463Nov 10 05:44 PM
Sinha VikasEVP & CFONov 06Sale195.005,6931,110,135162,770Nov 10 05:44 PM
Sinha VikasEVP & CFONov 03Option Exercise17.9630,000538,800192,770Nov 04 06:35 PM
Hallal DavidChief Operating OfficerNov 03Option Exercise20.3930,000611,736148,616Nov 04 06:36 PM
Islam SaqibSVP, Chief Strat & Port. Off.Nov 03Option Exercise89.2328,1252,509,59455,425Nov 04 06:36 PM
MACKAY MARTINEVP & Global Head of R&DNov 03Option Exercise104.869,375983,06333,801Nov 04 06:36 PM
MACKAY MARTINEVP & Global Head of R&DNov 03Sale191.529,3751,795,50024,426Nov 04 06:36 PM
Sinha VikasEVP & CFONov 03Sale190.9930,0005,729,619162,770Nov 04 06:35 PM
Hallal DavidChief Operating OfficerNov 03Sale190.0130,0005,700,287118,616Nov 04 06:36 PM
Islam SaqibSVP, Chief Strat & Port. Off.Nov 03Sale190.5028,1255,357,83127,300Nov 04 06:36 PM
Sinha VikasEVP & CFOOct 31Option Exercise17.9319,307346,186182,077Nov 04 06:35 PM
Sinha VikasEVP & CFOOct 31Sale195.1819,3073,768,340162,770Nov 04 06:35 PM
Moriarty John BSVP & General CounselOct 27Option Exercise92.6510,000926,50034,532Oct 28 05:41 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 27Option Exercise62.735,550348,140112,418Oct 28 05:41 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 27Sale188.585,9101,114,532106,508Oct 28 05:41 PM
Moriarty John BSVP & General CounselOct 27Sale189.4910,0001,894,93724,532Oct 28 05:41 PM
BURNS M MICHELEDirectorOct 17Buy167.32101,673788Dec 08 04:59 PM
Moriarty John BSVP & General CounselOct 06Option Exercise95.6510,000956,50034,532Oct 08 04:55 PM
Moriarty John BSVP & General CounselOct 06Sale179.0010,0001,790,00024,532Oct 08 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Option Exercise42.6610,025427,667116,893Oct 07 08:13 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Sale172.4110,0251,728,374106,868Oct 07 08:13 PM
BELL LEONARDCEOSep 26Sale165.1260,0009,906,901948,886Sep 26 05:52 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerSep 24Sale159.507612,122106,868Sep 26 05:53 PM
BELL LEONARDCEOSep 18Sale161.4512,3882,000,0431,008,886Sep 18 05:33 PM
BELL LEONARDCEOSep 16Option Exercise17.6532,047565,6301,053,321Sep 18 05:33 PM
BELL LEONARDCEOSep 16Sale160.2632,0475,136,0051,021,274Sep 18 05:33 PM
BELL LEONARDCEOSep 10Sale165.3812,1992,017,4711,021,274Sep 12 08:59 PM
Carmichael ClareSVP, Chief HR OfficerSep 02Sale169.4630451,51616,272Sep 04 04:34 PM